The discovery of the serum prostate specific antigen (PSA) in the early 1990s resulted in a sudden increase in population screening for prostate cancer with associated aggressive treatment that resulted in overtreatment among certain populations [29]. Here, KLK3 is linked to prostate carcinoma.